Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Desmopressin testing in von Willebrand disease: Lowering the burden.
Heijdra JM, Atiq F, Al Arashi W, Kieboom Q, Wuijster E, Meijer K, Kruip MJHA, Leebeek FWG, Cnossen MH; OPTI‐CLOT Study Group. Heijdra JM, et al. Among authors: al arashi w. Res Pract Thromb Haemost. 2022 Sep 26;6(6):e12784. doi: 10.1002/rth2.12784. eCollection 2022 Aug. Res Pract Thromb Haemost. 2022. PMID: 36186107 Free PMC article.
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.
van Moort I, Preijers T, Bukkems LH, Hazendonk HCAM, van der Bom JG, Laros-van Gorkom BAP, Beckers EAM, Nieuwenhuizen L, van der Meer FJM, Ypma P, Coppens M, Fijnvandraat K, Schutgens REG, Meijer K, Leebeek FWG, Mathôt RAA, Cnossen MH; OPTI-CLOT study group. van Moort I, et al. Lancet Haematol. 2021 Jul;8(7):e492-e502. doi: 10.1016/S2352-3026(21)00135-6. Lancet Haematol. 2021. PMID: 34171280 Clinical Trial.
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
Heijdra JM, Al Arashi W, de Jager NCB, Cloesmeijer ME, Bukkems LH, Zwaan CM, Leebeek FWG, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. Heijdra JM, et al. Among authors: al arashi w. BMJ Open. 2022 Feb 15;12(2):e049493. doi: 10.1136/bmjopen-2021-049493. BMJ Open. 2022. PMID: 35168962 Free PMC article.
Functional characterization of a nanobody-based glycoprotein VI-specific platelet agonist.
Zivkovic M, Pols-van Veen E, van der Vegte V, Sebastian SAE, de Moor AS, Korporaal SJA, Schutgens REG, Urbanus RT; Thrombocytopathy in the Netherlands (TiN) study group; SYMPHONY consortium. Zivkovic M, et al. Res Pract Thromb Haemost. 2024 Oct 3;8(7):102582. doi: 10.1016/j.rpth.2024.102582. eCollection 2024 Oct. Res Pract Thromb Haemost. 2024. PMID: 39512585 Free PMC article.
Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders.
van Hoorn ES, Willems SPE, Al Arashi W, de Moor AS, van Kwawegen CB, Teela L, Oude Voshaar MAH, Kremer Hovinga ICL, Schutgens REG, Schols SEM, Leebeek FWG, Haverman L, Cnossen MH, Gouw SC, Lingsma HF; SYMPHONY consortium and the Dutch research group for PROMIS implementation in inherited bleeding disorders. van Hoorn ES, et al. Among authors: al arashi w. Res Pract Thromb Haemost. 2024 Jun 13;8(4):102474. doi: 10.1016/j.rpth.2024.102474. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 39076727 Free PMC article.
Transcriptional and functional profiling identifies inflammation and endothelial-to-mesenchymal transition as potential drivers for phenotypic heterogeneity within a cohort of endothelial colony forming cells.
Laan SNJ, de Boer S, Dirven RJ, van Moort I, Kuipers TB, Mei H, Bierings R, Eikenboom J; SYMPHONY consortium. Laan SNJ, et al. J Thromb Haemost. 2024 Jul;22(7):2027-2038. doi: 10.1016/j.jtha.2024.03.018. Epub 2024 Apr 2. J Thromb Haemost. 2024. PMID: 38574861 Free article.
18 results